Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 4/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071818 | 0.83 | S1PR3 (0.46) | SLC2A1PARP1S1PR3KCNH2 | |
| SCHEMBL27428920 | 0.80 | MMP13 (0.47) | SLC2A1PARP1PDGFRBKDR | |
| SCHEMBL13761221 | 0.79 | LOXL2 (0.39) | KCNH2 | |
| SCHEMBL12312596 | 0.79 | CNR2 (0.44) | SLC2A1S1PR3KCNH2 | |
| SCHEMBL1003082 | 0.79 | CYP1A2 (0.41) | SLC2A1PARP1S1PR3ADRB2KCNH2 | |
| SCHEMBL12871166 | 0.76 | PTPN7 (0.49) | KCNH2 | |
| SCHEMBL13365636 | 0.76 | GABRA1 (0.44) | ADRB3 | |
| SCHEMBL1002024 | 0.75 | SLC2A1 (0.38) | SLC2A1PARP1S1PR3ADRB2KCNH2 | |
| SCHEMBL15697695 | 0.75 | ALDH1A1 (0.41) | SLC2A1PARP1S1PR3ADRB2ADRB1 | |
| SCHEMBL30779531 | 0.74 | TAAR1 (0.50) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | SLC6A5, SLC1A2, SLC18A2 | SLC2A1 44/4885PARP1 4047/4885S1PR3 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.